Department of Surgery, University of California, Irvine, California, USA.
School of Medicine, University of California, Irvine, California, USA.
J Surg Oncol. 2023 Nov;128(6):1021-1031. doi: 10.1002/jso.27448.
Cytoreductive surgery (CRS) has now been accepted as an integral component in the management of gastrointestinal and gynecological cancers with peritoneal metastases. Since the adoption of CRS is influenced by access to advanced medical facilities, trained multidisciplinary teams, and funding, there is wide variability in incorporation of CRS into routine clinical practice between high- versus low- and middle-income countries. This review highlights the global trends in the adoption of CRS for peritoneal malignancies with a specific focus on the establishment of CRS programs and barriers to incorporate CRS into routine clinical care in low- and middle-income countries.
细胞减灭术 (CRS) 现已被接受为胃肠道和妇科癌症伴腹膜转移的综合治疗的一个组成部分。由于接受 CRS 的影响因素包括能否获得先进的医疗设施、训练有素的多学科团队和资金，因此高收入与低收入和中等收入国家之间在将 CRS 纳入常规临床实践中的应用存在很大差异。本综述强调了全球范围内采用 CRS 治疗腹膜恶性肿瘤的趋势，特别关注在低收入和中等收入国家建立 CRS 项目以及将 CRS 纳入常规临床护理的障碍。
